现代制药(600420.SH)半年度净利润降9.27%至3.72亿元
格隆汇8月23日丨现代制药(600420.SH)发布2019年半年度报告,实现营业收入62.55亿元,同比增长6.87%;归属于上市公司股东的净利润3.72亿元,同比下降9.27%;归属于上市公司股东的扣除非经常性损益的净利润3.52亿元,同比下降9.63%;基本每股收益0.3525元。经营活动产生的现金流量净额6.55亿元,同比增长143.57%。
营销协同方面,推行“大区域战略”,以华东、华北、华南、东北、西南五大营销区域,全面推进区域营销标准化管理,加快实施区域营销一体化运营的步伐。并以各区域联动辐射,加大市场开拓和品牌推广范围,提高市场份额。通过开拓终端和零售市场,产品占有率和领域产品集中度提升,大品种销售实现同比增长6.50%。五大产品领域发展更趋平衡,市场抗风险能力得到提升。
工商协同方面,深化与国药控股商企协作,借助“批零一体化”网络资源和国药控股采购中心,工商协同份额同比持续提升。工医协同方面,借助国药集团平台优势,遴选公司重点强项产品,打通与国药集团下属医疗机构对接渠道,为进一步深入合作搭桥铺路。
报告期内70个项目正在开展一致性评价。同时公司持续提升研发项目质量,公司上报的研发项目中,4项被确立为国药集团重大项目,6项被确立为国药集团重点项目。开展新品种研发项目67项,工艺改进和技术升级项目37项。4个项目获批省市级资金资助,4个项目获批补充申请批件,新申请专利4项,新授权专利13项,获得省市级科技奖励2项。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.